ALT Altimmune posts 105 revenue growth but misses Q4 earnings estimates by 102 sparking 675 stock decline How Otter Tail OTTR prepares for market disruptions Q4 2025 Profit Disappoints ERO Ero Copper Q4 2025 EPS narrowly misses analyst estimates as shares log slight gains The edge Xilio Therapeutics XLO has in a competitive landscape 246 20260506 Is Vontier Corporation VNT stock worth adding exposure to Q4 2025 EPS Beats Forecasts JDcom Inc JD Broad Analyst Bullishness Driven by Profit Optimization and Segment Recovery Trajectory SYPR Sypris Solutions shares decline 4 as yearoveryear revenue drops 145 raising margin concerns What would it take for Regencell RGC to double from here 033 20260505